The Primary Obesity Surgery Endoluminal 2.0 Enfolding Technique (POSE 2.0et): Mo

Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA. *********.******@****.***. No abstract available Keywords: Endoscopy; Gastric remodeling; Metabolism; Obesity; Weight loss.

Role of Endoscopic Gastroplasty Techniques in the Management of Obesity - Clinical Endoscopy

Endoluminal bariatric procedures, which are performed using flexible... as a primary obesity procedure that seeks outcomes similar to those of traditional bariatric surgery with reduced...

Primary obesity surgery endoluminal (POSE) for the treatment of obesity: a syste

Abstract Background: Primary obesity surgery endoluminal (POSE) utilizes an incision-less operating platform system to create full-thickness plications in the gastric fundus and body...

Mechanism of action and selection of endoscopic bariatric therapies for treatment of obesity

Mechanism of action in weight loss, Devices in market, Total body weight loss at 12 mo (%), Duration of placement (mo) ; 1. Decrease gastric emptying, ReShape, 10–15, 6 ; 2. Increase gastric accommodation, Orbera, 10–12, 6 ; 3. Increased GLP-1 and PYY, Obalon, 5–10, 6 ; , BAROnova, 10–12, 12 ; 1. Aspiration of undigested food, AspireAssist, 15–20, >12 ; 2. Lifestyle modification associated with AT, AspireAssist, 15–20, >12 ; 1. Increased gastric restriction, ESG, 15–20, NA ; 2. Decreased gastric accommodation, POSE, 10–20, NA ; 3. Increased cholecystokinin, EGP, 7–12, NA ; Not well understood, Revita, Minimal, NA ; Not well understood, Diagone, Minimal, NA ; Anastomosis enhances the passage of partially undigested food into the distal ileum, increasing GLP-1 and PYY secretion, IMAS, 10–15, NA ; Anastomosis enhances the passage of partially undigested food into the distal ileum, increasing GLP-1 and PYY secretion, Magnamosis, Limited data, NA ; Anastomosis enhances the passage of partially undigested food into the distal ileum, increasing GLP-1 and PYY secretion, EasyByPass, Limited data, NA ; Undigested nutrients bypass the proximal intestine, increasing GLP-1 and PYY secretion, EndoBarrier, 15–20, 3–12 ; Undigested nutrients bypass the proximal intestine, increasing GLP-1 and PYY secretion, ValenTx, Limited data, Limited data

Mechanism of action and selection of endoscopic bariatric therapies for treatment of obesity

2) TransPyloric Shuttle ; 3) Weight loss mechanism ; 4) Outcomes ; 1) Device description and indicationsThe aspiration technique involves using a gastrostomy tube and siphon assembly to aspirate gastric content from the patients’ stomach 20 minutes after meals thrice daily.39 Importantly, the timing of aspiration after the meal determines the efficacy of AT. Aspiration 20 minutes after a 450-kcal meal is ingested removes approximately 30% of undigested calories, while aspirating after 60 miniu...

MULTICENTER PILOT RANDOMIZED CONTROLLED TRIAL EVALUATING THE EFFICACY OF THE PRIMARY OBESITY SURGERY ENDO....

Home · Access for Developing Countries · Articles In Press · Current Issue · List of Issues · Supplements · Audio Monthly Podcasts · Audio Quarterly Podcasts · Author Interviews · Spanish Podcast · VideoGIE · Videos · CME · Artificial Intelligence · Graphical Abstracts · About Open Access · Author Information · Figure Color Scheme · Permission to Reuse · Researcher Academy · Submit Your Manuscript · Journal Blog · About the Journal · About Open Acces...

Primary obesity surgery endoluminal (POSE-2) procedure for treatment of obesity

We studied the efficacy and safety of POSE-2 for obesity at 1 year in a real-world setting. Methods: We reviewed the records of 75 patients who underwent POSE-2 at our unit. The primary...

Endoscopic sleeve gastroplasty is feasible after failed modified primary obesity surgery endoluminal proc....

Abbreviations ; BMI (body mass index) · ESG (endoscopic sleeve gastroplasty) · POSE-2 (modified primary obesity surgery endoluminal)

Role of endoscopic duodenojejunal bypass liner in obesity management and glycemic control

Advantages, Disadvantages ; Reversible, Short duration of treatment (removed within 6–12 mo) ; Effective in T2DM control, Poor safety profile ; Considerable weight loss, Non-FDA approved ; , Need fluoroscopic assistance ; Reversible, Significant weight regain after removal, short duration of treatment (6–12 mo) ; Different models commercially available, ; 2-Years weight loss maintenance, Double-channel endoscope is required with the most used system (Overstitch; Apollo Endosurgery Inc.). However, a single channel device is now available (Overstitch Sx). ; FDA-approved, ; FDA-approved, Lower weight loss compared to other gastric remodeling techniques ; RCT data supporting its use, Non-reversible. ; Appears to be more durable than other remodeling techniques, Single channel scope and ultra-slim scope are required. ; Sustained long-term weight loss during its use, Complications similar to percutaneous endoscopic gastrostomy, such as granulation tissue formation, and buried-bumper syndrome ; Reversible, Gastrocutaneous fistula is common when used for more than 3 years. ; Promising results in terms of glycemic control and improvements in liver parameters in patients with NAFLD, Not effective for weight loss ; Reversible, Not widely available

Currently Available Non-balloon Devices

prImAry obEsIty surgEry ENDolumINAl Primary obesity surgery endoluminal (POSE) is one of the gastric restriction methods under FDA review (Fig. 2). This method uses the incisionless system...